[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

April 2016 | | ID: AB3E26C008FEN
La Merie Publishing

US$ 1,600.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Therapeutic monoclonal antibodies have become a clinically and commercially successful class of drugs. Branded therapeutic antibodies on the market reached global sales of US$ 91.5 bln in the year 2015, with a growth rate of 11.3% compared with the previous year. Despite the emergence of biosimilar antibodies due to patent expiries, validation of new targets, such as immune checkpoint moleucles, and of new antibody technologies enable the generation of innovative and IP-protected antibodies fostering further growth of the therapeutic antibody market. Among the enabling antibody technologies are
  • Fc-engineering of antibodies,
  • antibody-drug conjugates,
  • T-cell redirecting antibodies,
  • bispecific antibodies and
  • oligo- and polyclonal antibody formats.
These technologies also allow to revisit so far unsuccessful antibody targets. Immuno-oncology is one of the most dynamic R&D fields in the industry, so far mainly based on immune checkpoint inhibitor antibodies targeting PD-1 and PD-L1 alone and in combination with a vast variety of other approaches for cancer therapy.

Product description

Subscription to La Merie Publishing’s proprietary Antibody Database provides -as of April 2016 - online access to information about more than 3,400 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their
  • Technology (e.g. bispecifics, T-cell redirecting antibodies, antibody-drug conjugate, Fc-engineering, antibody format)
  • Target (e.g. VEGF, immuen checkpoint modulators)
  • Pipelines (selected by target, therapeutic area, company, technology)
  • Sales (for marketed antibodies)
  • R&D Phase (clinical phases, market, preclinical)
  • Territory (countrywise)
  • Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
  • Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antidoies on the market are provided. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.

Special Focus of the Database:
  • T-cell Redirecting Antibodies
  • Immune Checkpoint Modulatoring Antibodies
  • Antibody-Drug Conjugates
  • Bispecific Antibodies
  • Oligo- and Polyclonal Antgibodies
  • Biosimilar Antibodies
See our sample screenshots of the database: Download sample screenshots

Prerequisite: Internet access

Purchase of the subscription provides a 1-year online access to the data of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.

Benefits from the Antibody Pipeline Database:
  • Intuitive use
  • Continuously updated (input from e.g. press releases, scientific meetings, company presentations)
  • Designed for structured searches
  • Focused on targets, technologies, therapeutic areas and R&D phases
  • Ideal for competitor analysis (companies, targets, technologies, R&D phase)
  • Cost-effective and rapid solution for benchmarking
  • Identification of licensing candidates
Project listing in a tabular format:
  • Drug Codes
  • Target
  • Class of Compound
  • Company
  • Territory
  • Therapeutic Area
  • Indication
  • R&D Phase
Therapeutic Areas:
  • Cardiovascular & blood
  • Dermatology
  • Gastrointestinal
  • Genitourinary, renal & gynecology
  • Infectious & toxicology
  • Metabolism & endocrine
  • Neurology & psychiatry
  • Oncology
  • Ophthalmology & otorhinolaryngology
  • Orthopedics, dental, anesthesia & surgery
  • Pulmonary & respiratory
  • Rheumatoid & autoimmune
Predefined Technologies of the Scroll-Down Menu - examples:
  • T-Cell Redirecting Antibodies
  • Antibody-Drug Conjugates per Payload (e.g. Auristatin, PBD)
  • Bispecific Antibodies
  • Oligo- and Polyclonal Antibodies
  • In vitro generated Antibodies (phage display)
  • Fab Antibodies
  • Fc-Fusion Proteins
  • Agonist Antibodies
  • Transgenic Mouse Antibodies (e.g. XenoMouse, VelocImmune Mouse, KM Mouse)
  • Human Cell-Derived Antibodies
Predefined Targets of the Scroll Down Menu - examples:
  • Amyloid & Tau
  • Antibody Sales in 2015
  • Biosimilar Antibodies
  • BCMA
  • CD19
  • CD20
  • CD22
  • CD30
  • CD33
  • CD37
  • CD38
  • CD40/-L
  • CD123
  • CEA
  • CGRP
  • EGF-R
  • EpCAM
  • FGF/-R
  • GM-CSF
  • Her2
  • Interleukin-1/R
  • Interleukin-6/R
  • Interleukin-23 & 12/23
  • Interleukin-4/-13
  • Interleukin-17
  • LAG-3
  • Mesothelin
  • OX40/-L
  • PCSK9
  • PSMA
  • TIM-3
  • TNF
  • VEGF/R

More Publications